Flynn Daniel Lee 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Jul 24, 2020
Insider Transaction Report
Form 4
Flynn Daniel Lee
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-07-22−130,000→ 9,029 totalExercise: $1.89Exp: 2025-12-17→ Common Stock (130,000 underlying) - Exercise/Conversion
Common Stock
2020-07-22$1.89/sh+130,000$245,700→ 228,446 total
Holdings
- 91,020(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates.